Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Biosyent ( (TSE:RX) ) is now available.
BioSyent Inc. announced that its President and CEO, René Goehrum, will present at the LD Micro Invitational XV Conference in New York City on April 10, 2025. This presentation and subsequent one-on-one meetings with investors highlight BioSyent’s proactive approach to engaging with stakeholders and promoting its growth-oriented pharmaceutical business.
More about Biosyent
BioSyent Inc. is a growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol ‘RX’. It focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patients’ lives. The company markets its products through community, specialty, and international business units.
YTD Price Performance: -1.37%
Average Trading Volume: 4,163
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$123.9M
For a thorough assessment of RX stock, go to TipRanks’ Stock Analysis page.